Akcea and Ionis announce approval of TEGSEDI™ (inotersen) in the EU
Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, announced that TEGSEDITM (inotersen) has received marketing authorization approval from the EC for treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis. July 11, 2018